Nervous system

This is how tobacco damages our cells

Retrieved on: 
Friday, February 9, 2024

With the countless studies available today on the effects of tobacco use, we should have no trouble convincing ourselves and others of how harmful it is.

Key Points: 
  • With the countless studies available today on the effects of tobacco use, we should have no trouble convincing ourselves and others of how harmful it is.
  • The cells that make up our tissues, organs and body systems are sensitive to the effects of external toxic agents, many of which can be found in tobacco.
  • Many smokers not only accept this, but also ignore the serious danger it poses to the people around them.

Initial effects in the mouth and pharynx

  • When tobacco smoke enters our body, the first cells to receive it are in the mouth, nose and throat.
  • These effects on the immune system are also linked to a higher likelihood of developing cancer.
  • We also cannot forget that tobacco smoke robs us of our sense of taste and smell, leaving an almost continuous bitter taste in the mouth.

Lung damage

  • Furthermore, due to the direct damage caused by tobacco on the tissue that maintains the structure of the lungs, the bronchi and bronchioles become blocked, generating symptoms similar to suffocation.
  • As if that were not enough, people with COPD are also more likely to develop cardiovascular disease, and lung cancer.

Black tar and macrophages

  • We can cast our minds back to the previous image of my father’s pipe, black and sticky with tar.
  • It so happens that the lungs are rich in macrophages – special cells that play a key role in our immune systems by reacting to attacks, producing inflammatory responses.
  • These cells end up ingesting the tar from tobacco, and they eventually die loaded with this substance which builds up and gives a smoker’s lungs their characteristic blackened appearance.

Nicotine’s effects on neurons: dependence and addiction

  • As with any other compound that stimulates neurotransmitter receptors, permanent stimulation desensitises neurons.
  • This means that the neurons reduce the number of receptors, or change their sensitivity to the stimulant.
  • This desensitisation process can lead not only to nicotine dependence, but also to other diseases such as memory loss.


Guillermo López Lluch is a member of the Spanish Society of Cell Biology, the Spanish Society of Biochemistry and Molecular Biology, the Spanish Society of Geriatrics and Gerontology, the Society for Free Radical Research and the International Coenzyme Q10 Association. The research carried out by the author is financed by public funds from the Spanish Government or the Autonomous Government of Andalusia.

Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders

Retrieved on: 
Thursday, February 8, 2024

Proceeds from the financing will be used to advance the company’s pipeline of wholly-owned, off-the-shelf cell therapies for multiple indications, including its lead investigational candidate, NRTX-1001.

Key Points: 
  • Proceeds from the financing will be used to advance the company’s pipeline of wholly-owned, off-the-shelf cell therapies for multiple indications, including its lead investigational candidate, NRTX-1001.
  • “Neurona has pioneered development of a fully-differentiated cell therapy for drug-resistant focal epilepsy that is designed to be disease-modifying, repairing the affected neural network, and is yielding very promising initial clinical data.
  • It signifies the conviction that Neurona’s cell therapies have the potential to transform the treatment of previously refractory, devastating neurological disorders.
  • These subjects received a one-time administration of NRTX-1001 as well as temporary immunosuppression to promote the long-term persistence of the cell therapy.

Press release - MEPs adopt new rules to limit exposure to harmful substances at the workplace

Retrieved on: 
Wednesday, February 7, 2024

MEPs adopt new rules to limit exposure to harmful substances at the workplace

Key Points: 
  • MEPs adopt new rules to limit exposure to harmful substances at the workplace
    - Rules for exposure to lead updated for the first time in 40 years
    - Limit values for diisocyanates for first time ever
    - Better protection for those working to ensure the green transition
    On Wednesday, Parliament adopted new exposure limit values for lead for the first time in forty years and for diisocyanates for the first time ever.
  • Both substances are widely used to renovate buildings and to produce batteries, wind turbines, and to make electric vehicle lighter.
  • By limiting their exposure to these chemicals, the EU is protecting those working in the green transition.
  • Past exposure to lead
    Some workers have been exposed to lead over several years and have accumulated blood-lead levels well above any new limit value.

Autonomix Medical, Inc. Receives Ethics Committee Authorization for Proof-of-Concept Human Clinical Study Evaluating Proprietary Ablation Technology for Treatment of Pancreatic Cancer Pain

Retrieved on: 
Tuesday, February 6, 2024

THE WOODLANDS, TX, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has received authorization from the Uzbekistan Ethics Committee to open the clinical trial site for its proof-of-concept human clinical study evaluating the use of transvascular ablation for the treatment of pancreatic cancer pain. The Company is on track to commence enrollment in the first quarter of 2024.

Key Points: 
  • “Our team remains focused on the successful execution of our clinical path forward for this potentially groundbreaking technology.
  • We are making solid progress with the study and expect to initiate enrollment imminently,” commented Lori Bisson, Chief Executive Officer of Autonomix.
  • The primary objective of the proof-of-concept study is to successfully ablate relevant somatic nerves and mitigate pain in patients with pancreatic cancer pain utilizing RF ablation in a transvascular approach to the nerves in the region.
  • Twenty (20) subjects will be enrolled at one clinical trial site in Uzbekistan for the study.

How much weight do you actually need to lose? It might be a lot less than you think

Retrieved on: 
Monday, February 5, 2024

But type “setting a weight loss goal” into any online search engine and you’ll likely be left with more questions than answers.

Key Points: 
  • But type “setting a weight loss goal” into any online search engine and you’ll likely be left with more questions than answers.
  • They’ll typically use a body mass index (BMI) calculator to confirm a “healthy” weight and provide a goal weight based on this range.
  • Most sales pitches will suggest you need to lose substantial amounts of weight to be healthy – making weight loss seem an impossible task.

Using BMI to define our target weight is flawed

  • So it’s no surprise we use measurements and equations to score our weight.
  • BMI classifies bodies as underweight, normal (healthy) weight, overweight or obese and can be a useful tool for weight and health screening.


fails to consider two critical factors related to body weight and health – body fat percentage and distribution
does not account for significant differences in body composition based on gender, ethnicity and age.

How does losing weight benefit our health?

  • Losing just 5–10% of our body weight – between 6 and 12kg for someone weighing 120kg – can significantly improve our health in four key ways.
  • But research shows improvements in total cholesterol, LDL cholesterol and triglyceride levels are evident with just 5% weight loss.
  • Excess weight is linked to high blood pressure in several ways, including changing how our sympathetic nervous system, blood vessels and hormones regulate our blood pressure.
  • A meta-analysis of 25 trials on the influence of weight reduction on blood pressure also found every kilo of weight loss improved blood pressure by one point.
  • Research shows just 7% weight loss reduces risk of developing type 2 diabetes by 58%.
  • In one study each kilogram of weight loss resulted in a fourfold decrease in the load exerted on the knee in each step taken during daily activities.

Focus on long-term habits

  • An analysis of 29 long-term weight-loss studies found participants regained more than half of the weight lost within two years.
  • When we lose weight, we take our body out of its comfort zone and trigger its survival response.
  • Read more:
    What's the 'weight set point', and why does it make it so hard to keep weight off?


losing weight in small manageable chunks you can sustain, specifically periods of weight loss, followed by periods of weight maintenance, and so on, until you achieve your goal weight
making gradual changes to your lifestyle to ensure you form habits that last a lifetime.
Setting a goal to reach a healthy weight can feel daunting. But it doesn’t have to be a pre-defined weight according to a “healthy” BMI range. Losing 5–10% of our body weight will result in immediate health benefits. At the Boden Group, Charles Perkins Centre, we are studying the science of obesity and running clinical trials for weight loss. You can register here to express your interest.
Dr Nick Fuller works for the University of Sydney and has received external funding for projects relating to the treatment of overweight and obesity. He is the author and founder of the Interval Weight Loss program.

Ibogaine By David Dardashti Shares Insight On New Study By Stanford University

Retrieved on: 
Thursday, February 1, 2024

The study, which involved soldiers who had experienced both physical and psychological trauma, offers insight towards the potential therapeutic benefits of ibogaine.

Key Points: 
  • The study, which involved soldiers who had experienced both physical and psychological trauma, offers insight towards the potential therapeutic benefits of ibogaine.
  • The University of California has asserted that ibogaine has the ability to increase serotonin levels, which may contribute to the recovery of damaged brain cells.
  • Medicalnewstoday, a leading source of medical news and information, has also reported on the potential of ibogaine in promoting cell recovery.
  • Ibogaine By David Dardashti is proud to be at the forefront of this research and looks forward to further advancements in the field.

Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the Virtual Investor New to the Street Event

Retrieved on: 
Thursday, February 1, 2024

THE WOODLANDS, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will present at the Virtual Investor New to the Street Event on Wednesday, February 7, 2024 at 10:00 AM ET.

Key Points: 
  • As part of the event, Lori Bisson, Chief Executive Officer , Walter Klemp, Executive Chairman , Dr. Robert Schwartz, Chief Medical Officer , and Trent Smith, Chief Financial Officer of Autonomix Medical, will provide a corporate overview and business outlook.
  • In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event.
  • A live video webcast of the event will be available on the Events page under the Investors section of the Company’s website ( autonomix.com ).
  • A webcast replay will be available two hours following the live event and will be accessible for 90 days.

Autonomix Medical, Inc. to Ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024

Retrieved on: 
Wednesday, January 31, 2024

THE WOODLANDS, TX., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the Company will ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024 to celebrate the closing of its initial public offering and listing onto Nasdaq.

Key Points: 
  • THE WOODLANDS, TX., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the Company will ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024 to celebrate the closing of its initial public offering and listing onto Nasdaq.
  • Lori Bisson, Chief Executive Officer of Autonomix, will perform the honorary Nasdaq closing bell ringing ceremony to be held from 3:50 to 4:00 p.m.
  • The Company's executive management team, Board of Directors, family members and other supporters will join in the ceremony.
  • Ms. Bisson commented, “It is an honor to recognize the incredible efforts of our team and the significant achievement of closing our IPO and listing on Nasdaq.

Autonomix Medical, Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use – Over 100 patents in portfolio

Retrieved on: 
Tuesday, January 30, 2024

THE WOODLANDS, TX, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has regained exclusive worldwide rights to its technology for cardiology field use from Impulse Medical, Inc.

Key Points: 
  • In December 2021, Autonomix granted Impulse Medical, Inc., a license to its technology for use in the field of cardiology.
  • At the offering price of $5.00, the number of shares underlying the warrant is 1,600,000 shares of common stock at an exercise price of $0.001 per share.
  • Regaining the cardiology rights to our innovative technology broadens our development opportunities and provides further optionality related to our development strategy moving forward.
  • For more information about the Company’s technology, please visit autonomix.com .

Autonomix Medical, Inc. Completes Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use

Retrieved on: 
Tuesday, January 30, 2024

THE WOODLANDS, TX, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has regained exclusive worldwide rights to its technology for cardiology field use from Impulse Medical, Inc.

Key Points: 
  • In December 2021, Autonomix granted Impulse Medical, Inc., a license to its technology for use in the field of cardiology.
  • At the offering price of $5.00, the number of shares underlying the warrant is 1,600,000 shares of common stock at an exercise price of $0.001 per share.
  • Regaining the cardiology rights to our innovative technology broadens our development opportunities and provides further optionality related to our development strategy moving forward.
  • For more information about the Company’s technology, please visit autonomix.com .